Improving Adherence to Statin Therapy Through a Medication Management Application
ConditionAtherosclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
Interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, Mediteo GmbH, Heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.
Eligibility criteria
Qualifiers
Age >18 years
Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +/- 10 days of enrolment)
Statin naivety
LDL-C >100 mg/dl. No older than 21 days
Disqualifiers
Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia)
Patient has no own smartphone (no device provided for this study)
Prior drug therapy to lower LDL-C within the last 30 days
Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of <6 months
Trial design
Treatments tested in this trial
- Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)
Treatment groups
250 Participants
are divided into 2 treatment groupsLocations
1University Hospital, Essen45147, EssenNorth Rhine-Westphalia, Germany
Sponsors and collaborators
University Hospital, Essen
Lead sponsor
Source ClinicalTrials.gov